Is ContraFect Corp halal to invest in?

As of July 2026, ContraFect Corp 22R.SG is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is ContraFect Corp a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ContraFect Corp using these criteria to determine its compliance status.

Can Muslims buy shares of ContraFect Corp?

Muslim investors may consider investing in ContraFect Corp if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is ContraFect Corp classified as NOT HALAL?

Musaffa determines the Shariah status of ContraFect Corp by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for ContraFect Corp updated?

The Shariah compliance status of ContraFect Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like ContraFect Corp become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of ContraFect Corp?

You can check the latest Shariah compliance status of ContraFect Corp on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ContraFect Corp 22R.SG

22R.SG Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, ContraFect Corp is classified as not halal.

NOT HALAL

Report Source: 2023 3rd Quarter Report

ContraFect Corp. Stock Analysis 22R.SG

Germany Health Care Nano Cap Report: Q3, 2023

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York and currently employs 23 full-time employees. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase, is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its exebacase is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.

Key Statistics of ContraFect Corp (22R.SG)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Open

Volume

P/E Ratio (TTM)

Financial Metrics & Statements of ContraFect Corp (22R.SG)

Super Investors Invested in ContraFect Corp (22R.SG)

FAQ's for ContraFect Corp (22R.SG)

As of July 2026, ContraFect Corp 22R.SG is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ContraFect Corp using these criteria to determine its compliance status.
Muslim investors may consider investing in ContraFect Corp if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of ContraFect Corp by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of ContraFect Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of ContraFect Corp on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.